---
title: "300357.SZ (300357.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300357.SZ/news.md"
symbol: "300357.SZ"
name: "300357.SZ"
parent: "https://longbridge.com/en/quote/300357.SZ.md"
datetime: "2026-05-20T06:09:07.637Z"
locales:
  - [en](https://longbridge.com/en/quote/300357.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300357.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300357.SZ/news.md)
---

# 300357.SZ (300357.SZ) — Related News

### [With a penetration rate of only 1%, an underestimated hundred billion market has been launched!](https://longbridge.com/en/news/284086448.md)
*2026-04-25T15:15:13.000Z*
> The domestic AIT market is undergoing a reshaping of its competitive landscape. The market, previously dominated by Wolw

### [Wolwo Pharma: Net profit in the first quarter was 119 million yuan, a year-on-year increase of 60.38%](https://longbridge.com/en/news/283818273.md)
*2026-04-23T11:11:07.000Z*
> Wolwo Pharma announced that its operating revenue in the first quarter of 2026 was 253 million yuan, a year-on-year incr

### [At the shareholders' meeting of Jianya, the merger with Yiwei through stock exchange and the OTC listing plan were approved with the support of the National Development Fund](https://longbridge.com/en/news/283605400.md)
*2026-04-22T05:57:29.000Z*
> The Jianya shareholders' meeting was held on the 22nd, supporting the share swap merger with Yiwei, which received 57% a

### [Wolwo Pharma: The first subject has been enrolled in the Phase II clinical trial of the house dust mite membrane agent](https://longbridge.com/en/news/282002474.md)
*2026-04-08T08:30:06.000Z*
> Wolwo Pharma announced that the first subject enrollment for the Phase II clinical trial of its developed "house dust mi

### [The Taiwan stock market rebounded due to improved cross-strait relations and a recovery in technology stocks, boosting investor confidence](https://longbridge.com/en/news/281966351.md)
*2026-04-08T03:20:04.000Z*
> Taiwan's stock market rebounded due to cross-strait relations and the recovery of technology stocks, with the market hol

### [Johnson & Johnson plans to increase its stake in Jena by up to 350 million and intends to appoint directors and declare the acquisition](https://longbridge.com/en/news/281889086.md)
*2026-04-07T13:15:52.000Z*
> Johnson & Johnson's board has decided to increase its investment in Jena, with plans to invest no more than NT$ 350 mill

### [Jianya issued a statement in response to Johnson & Johnson: The merger with Huawai not only focuses on short-term financial evaluation but also emphasizes long-term industrial layout and the establishment of competitive advantages](https://longbridge.com/en/news/279933735.md)
*2026-03-20T11:21:24.000Z*
> Jianya (4130) responded to Johnson & Johnson (4747)'s concerns, emphasizing that the share swap merger with Ewei (1799) 

### [Wolwo Pharma has received acceptance for the clinical trial application of human umbilical cord mesenchymal stem cell type II injection](https://longbridge.com/en/news/278687072.md)
*2026-03-11T08:54:07.000Z*
> Wolwo Pharma announced that its indirectly controlled subsidiary, Zhejiang Wolwo Stem Cell Technology Co., Ltd., has rec